利妥昔单抗及其在自身免疫性大疱性疾病中的应用。

Rituximab and its use in autoimmune bullous disorders.

机构信息

Department of Dermatology, St George Hospital, Gray Street, Kogarah, Sydney, NSW 2217, Australia.

出版信息

Immunol Allergy Clin North Am. 2012 May;32(2):331-7, viii. doi: 10.1016/j.iac.2012.04.013. Epub 2012 Apr 18.

DOI:10.1016/j.iac.2012.04.013

Abstract

Rituximab is a chimeric, murine-human, monoclonal antibody against the CD20 antigen of B lymphocytes. It has been used off-label to treat and manage autoimmune and dermatologic diseases as an alternative or adjuvant therapy to systemic treatments. Due to cost, potential complications, and lack of data rituximab is used after standard systemic therapies have failed or the patient is absolutely contraindicated for corticosteroids. More research is required.

摘要

利妥昔单抗是一种嵌合的、鼠-人源、针对 B 淋巴细胞 CD20 抗原的单克隆抗体。它已被超适应证用于治疗和管理自身免疫和皮肤病学疾病，作为全身治疗的替代或辅助治疗。由于成本、潜在并发症和缺乏数据，利妥昔单抗仅在标准全身治疗失败或患者绝对禁忌使用皮质类固醇时使用。还需要更多的研究。